These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3332123)

  • 1. Marrow transplantation for non-Hodgkin's lymphoma: a multi-centre study from the European Co-operative Bone Marrow Transplant Group.
    Ernst P; Maraninchi D; Jacobsen N; Kolb HJ; Bordigoni P; Ljungman P; Bandini G; Parker AC; Volin L; Powles R
    Bone Marrow Transplant; 1986 May; 1(1):81-6. PubMed ID: 3332123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
    Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
    Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
    Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
    Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma.
    Cervantes F; Shu XO; McGlave PB; Ramsay NK; Miller WJ; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1995 Sep; 16(3):387-92. PubMed ID: 8535311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic marrow transplantation in non-Hodgkin's lymphoma.
    Copelan EA; Kapoor N; Gibbins B; Tutschka PJ
    Bone Marrow Transplant; 1990 Jan; 5(1):47-50. PubMed ID: 2404530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
    van Besien KW; Mehra RC; Giralt SA; Kantarjian HM; Pugh WC; Khouri IF; Moon Y; Williams P; Andersson BS; Przepiorka D; McCarthy PL; Gajewski JL; Deisseroth AB; Cabanillas FF; Champlin R
    Am J Med; 1996 Mar; 100(3):299-307. PubMed ID: 8629675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement.
    Bird JM; Luger S; Mangan P; Edelstein M; Silberstein L; Powlis W; Ball J; Schultz DJ; Stadtmauer EA
    Bone Marrow Transplant; 1996 Aug; 18(2):309-13. PubMed ID: 8864439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.